Displaying drugs 11051 - 11075 of 12129 in total
IDD-3
IDD-3 is a therapeutic specific immunostimulant developed by IDM Pharma in partnership with sanofi-aventis. It consists of mature dendritic cells loaded with lysates from melanoma tumor cell lines. It includes Dendritophages that are dendritic cells, a type of specialized immune cells derived from the patient's own white blood cells.
Investigational
Matched Description: … IDD-3 is a therapeutic specific immunostimulant developed by IDM Pharma in partnership with sanofi-aventis ... It includes Dendritophages that are dendritic cells, a type of specialized immune cells derived from …
Thienylfentanyl
Thienylfentanyl is a fentanyl analog analgesic that was sold on the black market in the 1980s until the Federal Analog Act scheduled drugs based on structural similarity rather than scheduling drugs individually. Thienylfentanyl has a similar synthesis pathway to fentanyl except 2-(2-bromoethyl)thiophene is substituted for phenethyl bromide.
Illicit
Matched Description: … Thienylfentanyl is a fentanyl analog analgesic that was sold on the black market in the 1980s until the ... Thienylfentanyl has a similar synthesis pathway to fentanyl except 2-(2-bromoethyl)thiophene is substituted …
OTL-201
OTL-201 is an investigational hematopoietic stem cell (HSC) gene therapy being developed by Orchard Therapeutics for the treatment of mucopolysaccharidosis type IIIA (MPS-IIIA). It consists of a lentiviral vector to insert a functional copy of the human N-Sulfoglucosamine Sulfohydrolase (SGSH) gene into autologous CD34+ hematopoietic stem cells.
Investigational
Matched Description: … It consists of a lentiviral vector to insert a functional copy of the human N-Sulfoglucosamine Sulfohydrolase …
Dimenoxadol
Dimenoxadol is an opioid analgesic which produces typical opioid effects such as analgesia and sedation. It is structurally similar to methadone and is a benzilic acid derivative. In the United States it is classified as a Schedule I controlled drug.
Experimental
Illicit
Matched Description: … In the United States it is classified as a Schedule I controlled drug. ... It is structurally similar to methadone and is a benzilic acid derivative. …
4-(4-fluoro-phenylazo)-5-imino-5H-pyrazol-3-ylamine
4-(4-fluoro-phenylazo)-5-imino-5H-pyrazol-3-ylamine is a solid. This compound belongs to the fluorobenzenes. These are compounds containing one or more fluorine atoms attached to a benzene ring. This substance targets the protein methionine aminopeptidase.
Experimental
Matched Description: … 4-(4-fluoro-phenylazo)-5-imino-5H-pyrazol-3-ylamine is a solid. ... These are compounds containing one or more fluorine atoms attached to a benzene ring. …
Trefentanil
Trefentanil (A-3665) is a fentanyl analogue opioid developed in 1992. It is more potent and shorter acting than alfentanil. Trefentanil is not used in clinics due to the severity of its respiratory depression, though it is still used in research.
Experimental
Matched Description: … Trefentanil (A-3665) is a fentanyl analogue opioid developed in 1992. …
Bempegaldesleukin
Bempegaldesleukin is under investigation in clinical trial NCT03729245 (A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)).
Investigational
Matched Description: … Bempegaldesleukin is under investigation in clinical trial NCT03729245 (A Study of NKTR-214 in Combination ... With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy …
OSI-7836
OSI-7836 is a member of the nucleoside class of cytotoxic drugs of which gemcitabine is the market leader. OSI Pharmaceuticals develops OSI-7836 as a next-generation gemcitabine. The anti-tumor activity of OSI-7836 appeares to be less schedule dependent than gemcitabine. It is also more active than ara-C (another clinically used nucleoside...
Investigational
Matched Description: … OSI Pharmaceuticals develops OSI-7836 as a next-generation gemcitabine. ... OSI-7836 is a member of the nucleoside class of cytotoxic drugs of which gemcitabine is the market leader …
Dutogliptin
Dutogliptin has been investigated for the treatment of Diabetes Mellitus, Type II.
Investigational
Elsiglutide
Investigational
DG041
DG041 is a novel, first-in-class, orally-administered small molecule developmented for the prevention of arterial thrombosis and its complications.
DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of the EP3 receptor for prostaglandins E2. EP3 is a target that associates with increased risk of various vascular...
Investigational
Matched Description: … EP3 is a target that associates with increased risk of various vascular diseases. ... DG041 is a novel, first-in-class, orally-administered small molecule developmented for the prevention ... DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of the EP3 receptor …
EGS21
EGS21(TM) is a beta-D-glucosylceramide (GC) compound. It is a potential therapeutic for treating immune mediated disorders. GC is a glycolipid that has been shown by Enzo scientists and collaborators to act as an anti-inflammatory agent in animal model systems, and therefore is being evaluated as an important candidate drug in...
Investigational
Matched Description: … EGS21(TM) is a beta-D-glucosylceramide (GC) compound. ... It is a potential therapeutic for treating immune mediated disorders. ... GC is a glycolipid that has been shown by Enzo scientists and collaborators to act as an anti-inflammatory …
Latrunculin B
Latrunculin B is a 14-membered macrolide attached to 2-thiazolidinone moiety, isolated from Red Sea sponge Latrunculia magnifica.
Experimental
Matched Description: … Latrunculin B is a 14-membered macrolide attached to 2-thiazolidinone moiety, isolated from Red Sea sponge …
Solithromycin
Solithromycin is a ketolide antibiotic undergoing clinical development for the treatment of community-acquired pneumonia (CAP) and other infections.
Investigational
Matched Description: … Solithromycin is a ketolide antibiotic undergoing clinical development for the treatment of community-acquired …
Navicixizumab
Navicixizumab is under investigation in clinical trial NCT02298387 (A Phase 1 Study of Navicixizumab in Subjects With Solid Tumors).
Investigational
Matched Description: … Navicixizumab is under investigation in clinical trial NCT02298387 (A Phase 1 Study of Navicixizumab …
Pegapamodutide
Pegapamodutide is under investigation in clinical trial NCT02188303 (A Study of LY2944876 in Healthy Japanese and Non-Japanese Participants).
Investigational
Matched Description: … Pegapamodutide is under investigation in clinical trial NCT02188303 (A Study of LY2944876 in Healthy …
TAS-116
TAS-116 is under investigation in clinical trial NCT02965885 (A Study of TAS-116 in Patients With Solid Tumors).
Investigational
Matched Description: … TAS-116 is under investigation in clinical trial NCT02965885 (A Study of TAS-116 in Patients With Solid …
LY-2623091
LY-2623091 is under investigation in clinical trial NCT02194465 (A Study of LY2623091 in Participants With High Blood Pressure).
Investigational
Matched Description: … LY-2623091 is under investigation in clinical trial NCT02194465 (A Study of LY2623091 in Participants …
E59
E59 is a humanized IgG1 low affinity allergic reactivity inhibiting (LARI) monoclonal antibody. It was developed by Sixal Inc.
Investigational
Matched Description: … E59 is a humanized IgG1 low affinity allergic reactivity inhibiting (LARI) monoclonal antibody. …
Epaminurad
Epaminurad is under investigation in clinical trial NCT05815901 (A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients).
Investigational
Matched Description: … Epaminurad is under investigation in clinical trial NCT05815901 (A Therapeutic Confirmatory Study of …
Rezpegaldesleukin
Rezpegaldesleukin is under investigation in clinical trial NCT04433585 (A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)).
Investigational
Matched Description: … Rezpegaldesleukin is under investigation in clinical trial NCT04433585 (A Study of LY3471851 in Adults …
NasoVAX
NasoVAX contains replication-deficient adenovirus vectors in suspension. It is a vaccine administered through a nasal spray that expresses influenza hemagglutinin in nasal epithelial cells . Created by Altimmune, Inc., NasoVAX is currently being developed for seasonal and pandemic use as it can activate humoral and cellular immune responses. The compound...
Investigational
Matched Description: … It is a vaccine administered through a nasal spray that expresses influenza hemagglutinin in nasal epithelial ... As of June 2020, NasoVAX is being evaluated in a Phase 2 clinical trial for safety and effectivness in ... compound has already shown to be tolerated with no adverse effects or fever in healthy individuals with a …
Clomocycline
Clomocycline is a tetracycline used to treat bacterial infections.
Experimental
Matched Description: … Clomocycline is a tetracycline used to treat bacterial infections. …
INCB3284
INCB3284 is a CCR2 antagonist for Inflammation-driven Diseases.
Investigational
Matched Description: … INCB3284 is a CCR2 antagonist for Inflammation-driven Diseases. …
Tezacitabine
A synthetic purine nucleoside analogue with potential antineoplastic activity.
Investigational
Matched Description: … A synthetic purine nucleoside analogue with potential antineoplastic activity. …
Displaying drugs 11051 - 11075 of 12129 in total